Prostate cancer | Editor-in-chief: Amit Bahl

Diagnosing clinically significant PCa

Background

Diagnosing PCa should focus on detecting clinically significant PCa. Insignificant tumours are preferably not found, since there is a strong link between overdetection and overtreatment that is very hard to break.

Educational Objective

Aim of this course is to provide insight into the most appropriate diagnostic options for distinct patient profiles.

Specialty

Urology

Target Audience

CME (basic), Residents (senior)

Latest update

November 1, 2018

Metastatic hormone-sensitive PCa: new standards of care

Background

Guidelines on 1st- and 2nd-line treatment of patients with metastatic hormone-sensitive prostate cancer have recently changed due to new evidence from clinical studies.

Educational Objective

To study the new data and guidelines and learn to apply these in different patient cases.

Specialty

Urology, Medical oncology

Target Audience

CME (intermediate-advanced), Residents (senior)

Latest update

October 1, 2018

Adverse pathology at radical prostatectomy

Background

Patients who present with adverse pathology at RP + extended pelvic lymph node extension (ePLND) are at higher risk of recurrence. The most appropriate therapy for these patients differs according to the type and number of adverse features.

Educational Objective

Aim of this course is to provide insights into the most appropriate treatment of patients presenting with adverse pathology at RP + ePLND.

Specialty

Urology, Radiation oncology, Medical oncology

Target Audience

CME (basic), Residents (senior)

Latest update

November 1, 2018

Biochemical recurrence after radical prostatectomy

Background

Biochemical recurrence (BCR) occurs in a significant proportion of patients who received primary curative treatment for localised PCa. Multiple clinical factors must be taken into account to optimally treat a patient with N0 M0 PSA-recurrent PCa.

Educational Objective

Aim of this course is to provide insights into the most appropriate treatment options of men presenting with BCR after radical prostatectomy (RP).

Specialty

Urology, Radiation oncology, Medical oncology

Target Audience

CME (basic), Residents (senior)

Latest update

November 1, 2018

First-line treatment of high-risk non-metastatic PCa

Background

Most patients with high-risk prostate cancer (PCa) will need a multimodal treatment approach, combining different modalities such as radical prostatectomy (RP), radiation therapy (RT), and androgen-deprivation therapy (ADT).

Educational Objective

This course aims to provide insight into the most appropriate 1st-line treatment options.

Specialty

Urology, Radiation oncology, Medical oncology

Target Audience

CME (basic), Residents (senior)

Latest update

November 1, 2018

Radical treatment of low- and intermediate-risk PCa

Background

Men with PSA-detected clinically localised PCa have excellent 10-year survival rates irrespective of the treatment (ProtecT trial). Is treatment choice here just a matter of patient preference?

Educational Objective

Gain insight into the treatment choices for men with low- and intermediate-risk PCa, with a focus on radical treatments.

Specialty

Urology, Radiation oncology

Target Audience

CME (basic), Residents (senior)

Latest update

November 1, 2018

Active surveillance: yes or no?

Background

Overdiagnosis of indolent PCa still is prevalent due to PSA testing and often leads to overtreatment. A lot of men eligible for active surveillance according to international guidelines do receive radical therapy.

Educational Objective

The aim is to assess if a patient is a good candidate for active surveillance or not.

Specialty

Urology, Radiation oncology

Target Audience

CME (basic), Residents (senior)

Latest update

November 1, 2018